<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04821115</url>
  </required_header>
  <id_info>
    <org_study_id>2019_0075</org_study_id>
    <nct_id>NCT04821115</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Low-intensity Shockwave Therapy for Peyronie's Disease</brief_title>
  <acronym>ONDELA</acronym>
  <official_title>Safety and Efficacy of Low-intensity Shockwave Therapy for Peyronie's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dornier MedTech Systems</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of the effect of Low-intensity extracorporeal shockwave therapy (ESWT) for&#xD;
      Peyronie's disease (PD) via a single blind, sham-controlled, randomized clinical trial.&#xD;
      Investigators will not be blinded to group assignments, but penile curvature will be assessed&#xD;
      from coded patient pictures by a blinded assessor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of low intensity ESWT on penile curvature in erection in patients with Peyronie's disease</measure>
    <time_frame>15 months</time_frame>
    <description>Average change in penile curvature based on the pictures taken by the patient (face and profil) at baseline and after the 6 week follow-up.&#xD;
The assessment will be performed by a blinded assessor at the end of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the safety of ESWT on patients with PD: adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>Treatment related adverse events recorded at each visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the effect of ESWT on penile pain</measure>
    <time_frame>3 months</time_frame>
    <description>Patient complete at each visit a numeric rating scale of penile pain graduated from 0 (no pain) to 10 (worst pain) 0 means the patient has no pain and 10 for worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the effect of ESWT on sexual bother</measure>
    <time_frame>3 months</time_frame>
    <description>Difference of the score of the International Index of Erectile Function (IIEF-5) reported by the patient at baseline and after 6 week follow-up.&#xD;
The score is calculated through 5 questions with answers ranging from 0 to 5. Between 26 and 30, the score indicates no erectile dysfunction. Between 17 and 25, it indicates mild dysfunction. Between 11 and 16, it indicates a moderate dysfunction and below 10 a complete or severe dysfunction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Peyronie Disease</condition>
  <condition>Penile Diseases</condition>
  <arm_group>
    <arm_group_label>Low intensity choc waves therapy (Experimental group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will use the device with a real applicator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The patients will use the device with a sham applicator. Instead of a focusing lens, the applicator will have an internal foam piece that will dissipate the energy of the shockwave. Hence, the sham applicator will look, feel and sound the same as the active, but no measurable energy is emitted</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low intensity choc waves therapy (active applicator)</intervention_name>
    <description>At each of the 4 sessions, 4000 shockwaves will be delivered at level 8 (EFD = 0.133 mJ/mm2), over a period of 15 to 20 minutes. The probe will be applied directly to the plaque, on the flaccid penis. The device will stop automatically after the 4000 shock waves.</description>
    <arm_group_label>Low intensity choc waves therapy (Experimental group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham (sham applicator)</intervention_name>
    <description>At each of the 4 sessions, a sham applicator will be used. The sham applicator has an internal foam pad that disperses the shockwave energy, but is not visible from the outside. The sham applicator will look, feel and sound the same as the active, but no measurable energy is emitted.</description>
    <arm_group_label>Sham group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years old male,&#xD;
&#xD;
          -  Untreated Peyronie's disease (excepted oral therapy) (wash out: at least 1 month),&#xD;
&#xD;
          -  Single axis penile curvature in erection at 20 - 90 degrees at baseline,&#xD;
&#xD;
          -  Dorsal or lateral penile plaque,&#xD;
&#xD;
          -  Able and willing to perform ESWT self-treatment under supervision,&#xD;
&#xD;
          -  Able to understand and complete patient questionnaires,&#xD;
&#xD;
          -  Having sign an informed consent form prior to any study specific procedure,&#xD;
&#xD;
          -  Being covered by a national health insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Congenital penile deformity,&#xD;
&#xD;
          -  Hourglass deformity,&#xD;
&#xD;
          -  Circumferential plaque,&#xD;
&#xD;
          -  Septal or ventral plaque,&#xD;
&#xD;
          -  Plaque that cannot be palpated during clinical examination,&#xD;
&#xD;
          -  Previous intralesional injection for Peyronie's Disease,&#xD;
&#xD;
          -  Severe erectile dysfunction (EHS &lt; 3),&#xD;
&#xD;
          -  Current penile, malignancy,&#xD;
&#xD;
          -  Previous penile surgery except for circumcision or condyloma removal,&#xD;
&#xD;
          -  Previous pelvic radiation therapy,&#xD;
&#xD;
          -  Anti-coagulant medication, except acetylsalicylic acid up to 100mg daily,&#xD;
&#xD;
          -  Previous low-intensity focused shockwave therapy on penis,&#xD;
&#xD;
          -  Any other condition that would prevent the patient from completing the study, as&#xD;
             judged by the principal investigator,&#xD;
&#xD;
          -  Being deprived of liberty or under guardianship.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry LEBRET, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Foch</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thierry LEBRET, PhD</last_name>
    <phone>0146252431</phone>
    <phone_ext>+33</phone_ext>
    <email>t.lebret@hopital-foch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabeth Hulier-Ammar, PhD</last_name>
    <phone>0146251175</phone>
    <phone_ext>+33</phone_ext>
    <email>drci-promotion@hopital-foch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre d'Urologie du Polygone</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine FAIX, MD</last_name>
      <phone>04 67 20 21 83</phone>
      <phone_ext>+33</phone_ext>
      <email>a.faix34@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pasteur 2</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel CHEVALLIER, PhD</last_name>
      <phone>04 92 03 77 87</phone>
      <phone_ext>+33</phone_ext>
      <email>chevallier.d@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Foch hospital</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry LEBRET, PhD</last_name>
      <phone>0146252431</phone>
      <phone_ext>+33</phone_ext>
      <email>t.lebret@hopital-foch.com</email>
    </contact>
    <contact_backup>
      <last_name>François-Xavier MADEC, MD</last_name>
      <phone>0146252111</phone>
      <email>f.madec@hopital-foch.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric HUYGHE, PhD</last_name>
      <phone>05 61 32 27 31</phone>
      <phone_ext>+33</phone_ext>
      <email>huyghe.e@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penile Induration</mesh_term>
    <mesh_term>Penile Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

